Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 464

The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

Open access
BARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. CASTRO, CHAPMAN, M. JOHN, COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., FURBERG, C. D., GAGNE, C., HAFFNER, S. M., HUMPHRIES, S. E., JUNGNER, I., KRAUSS, R. M., KWITEROVICH, P., MARCOVINA, S., PACKARD, C. J., PEARSON, T. A., REDDY, K. SRINATH, ROSENSON, R., SARRAFZADEGAN, N., SNIDERMAN, A. D., STALENHOEF, A. F., STEIN, E., TALMUD, P. J., TONKIN, A. M., WALLDIUS, G., WILLIAMS, K. M. S.·2006·Journal of Internal Medicine

Abstract

Abstract.: There is abundant evidence that the risk of atherosclerotic vascular disease is directly related to plasma cholesterol levels. Accordingly, all of the national and transnational screening and therapeutic guidelines are based on total or LDL cholesterol. This presumes that cholesterol is the most important lipoprotein‐related proatherogenic risk variable. On the contrary, risk appears to be more directly related to the number of circulating atherogenic particles that contact and enter the arterial wall than to the measured concentration of cholesterol in these lipoprotein fractions. Each of the atherogenic lipoprotein particles contains a single molecule of apolipoprotein (apo) B and therefore the concentration of apo B provides a direct measure of the number of circulating atherogenic lipoproteins. Evidence from fundamental, epidemiological and clinical trial studies indicates that apo B is superior to any of the cholesterol indices to recognize those at increased risk of vascular disease and to judge the adequacy of lipid‐lowering therapy. On the basis of this evidence, we believe that apo B should be included in all guidelines as an indicator of cardiovascular risk. In addition, the present target adopted by the Canadian guideline groups of an apo B <90 mg dL−1 in high‐risk patients should be reassessed in the light of the new clinical trial results and a new ultra‐low target of <80 mg dL−1 be considered. The evidence also indicates that the apo B/apo A‐I ratio is superior to any of the conventional cholesterol ratios in patients without symptomatic vascular disease or diabetes to evaluate the lipoprotein‐related risk of vascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.2006.01616.x

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 105 references

Cited by

See all 464

Metadata

Authors
BARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. C., CHAPMAN, M. J., COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., FURBERG, C. D., GAGNE, C., HAFFNER, S. M., HUMPHRIES, S. E., JUNGNER, I., KRAUSS, R. M., KWITEROVICH, P., MARCOVINA, S., PACKARD, C. J., PEARSON, T. A., REDDY, K. S., ROSENSON, R., SARRAFZADEGAN, N., SNIDERMAN, A. D., STALENHOEF, A. F., STEIN, E., TALMUD, P. J., TONKIN, A. M., WALLDIUS, G., & WILLIAMS, K. M. S.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2006-02-10
Volume
259
Issue
3
Pages
247-258
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2045054080
Cited by
464
References
105
FWCI
44.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel. https://app.cochat.ai/papers/10.1111/j.1365-2796.2006.01616.x
The paper
BARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. C., CHAPMAN, M. J., COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., FURBERG, C. D., GAGNE, C., HAFFNER, S. M., HUMPHRIES, S. E., JUNGNER, I., KRAUSS, R. M., KWITEROVICH, P., MARCOVINA, S., PACKARD, C. J., . . . WILLIAMS, K. M. S. (2006). Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2006.01616.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.